News

PMCPA ANNUAL REPORT SHOWS A BUSY YEAR, WITH MORE COMPLAINTS IN 2016 THAN IN THE PREVIOUS TWO YEARS.

Astellas UK and Astellas Europe have brought discredit upon, and reduced confidence in, the pharmaceutical industry, in addition both have been publicly reprimanded. Pfizer Ltd, Novartis Pharmaceuticals UK Ltd and Tor Generics Ltd have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016.  This has been extended for a further 12 months.

Astellas UK and Gedeon Richter (UK) Ltd have brought discredit upon, and reduced confidence in, the pharmaceutical industry. Astellas UK has been publicly reprimanded and Gedeon Richter required to issue a corrective statement.​

All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

​The ABPI Code of Practice is in the process of being updated. In the meantime, the PMCPA is working on reviewing and updating its guidance. The PMCPA Compliance Network was asked to help with this and to identify possible short and long term changes to the Code. The Review Group and the ABPI Medical Expert Network and others have also contributed to the discussion. This is part of the ongoing work to ensure that the Code and its operation remain fit for purpose.

All five companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Boehringer Ingelheim and Eli Lilly and Company were required to issue a corrective statement.

All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Stirling Anglian was required to issue a corrective statement.

Both companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Astellas UK Limited and Astellas Europe have been required to issue corrective statements and have been publicly reprimanded. Both companies have been required to undergo audits and Astellas UK has been suspended from membership of the ABPI.

AstraZeneca and Genzyme have been named in advertisements following breaches of the ABPI Code of Practice for the Pharmaceutical Industry.¹

Today the Association of the British Pharmaceutical Industry is publishing details of payments and other benefits in kind made by the industry to healthcare professionals, healthcare organisations and other relevant decision makers.

Astellas UK is suspended from membership of the ABPI